Research ArticlePsoriatic Arthritis

Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

Atul Deodhar, Dafna D. Gladman, Iain B. McInnes, Sebastian Spindeldreher, Ruvie Martin, Luminita Pricop, Brian Porter, Jorge Safi Jr., Abhijit Shete and Gerard Bruin
The Journal of Rheumatology April 2020, 47 (4) 539-547; DOI: https://doi.org/10.3899/jrheum.190116

REFERENCES

  1. 1.↵
    1. Lubberts E
    . The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015;11:415–29.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Mitra A,
    2. Raychaudhuri SK,
    3. Raychaudhuri SP
    . Functional role of Il-22 in psoriatic arthritis. Arthritis Res Ther 2012;14:R65.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Raychaudhuri SP
    . Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013;44:183–93.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Sherlock JP,
    2. Joyce-Shaikh B,
    3. Turner SP,
    4. Chao CC,
    5. Sathe M,
    6. Grein J,
    7. et al.
    IL-23 induces spondyloarthropathy by acting on ROR- γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012;18:1069–76.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Blauvelt A,
    2. Prinz JC,
    3. Gottlieb AB,
    4. Kingo K,
    5. Sofen H,
    6. Ruer-Mulard M,
    7. et al;
    8. FEATURE Study Group
    . Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Rheumatol 2015;172:484–93.
    OpenUrl
  6. 6.↵
    1. Langley RG,
    2. Elewski BE,
    3. Lebwohl M,
    4. Reich K,
    5. Griffiths CE,
    6. Papp K,
    7. et al;
    8. ERASURE Study Group;
    9. FIXTURE Study Group
    . Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 2014;371:326–38.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Mrowietz U,
    2. Leonardi CL,
    3. Girolomoni G,
    4. Toth D,
    5. Morita A,
    6. Balki SA,
    7. et al;
    8. SCULPTURE Study Group
    . Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015;73:27–36.e1.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Paul C,
    2. Lacour JP,
    3. Tedremets L,
    4. Kreutzer K,
    5. Jazayeri S,
    6. Adams S,
    7. et al;
    8. JUNCTURE study group
    . Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: A randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015;29:1082–90.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. McInnes IB,
    2. Mease PJ,
    3. Kirkham B,
    4. Kavanaugh A,
    5. Ritchlin CT,
    6. Rahman P,
    7. et al;
    8. FUTURE 2 Study Group
    . Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137–46.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Mease PJ,
    2. McInnes IB,
    3. Kirkham B,
    4. Kavanaugh A,
    5. Rahman P,
    6. van der Heijde D,
    7. et al;
    8. FUTURE 1 Study Group
    . Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373:1329–39.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Nash P,
    2. Mease PJ,
    3. McInnes IB,
    4. Rahman P,
    5. Ritchlin CT,
    6. Blanco R,
    7. et al;
    8. FUTURE 3 study group
    . Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: Results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 2018;20:47.
    OpenUrl
  12. 12.↵
    1. Baeten D,
    2. Sieper J,
    3. Braun J,
    4. Baraliakos X,
    5. Dougados M,
    6. Emery P,
    7. et al;
    8. MEASURE 1 Study Group;
    9. MEASURE 2 Study Group
    . Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534–48.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Deodhar AA,
    2. Dougados M,
    3. Baeten DL,
    4. Cheng-Chung Wei J,
    5. Geusens P,
    6. Readie A,
    7. et al.
    Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol 2016;68:2901–10.
    OpenUrl
  14. 14.↵
    1. Kivitz AJ,
    2. Wagner U,
    3. Dokoupilova E,
    4. Supronik J,
    5. Martin R,
    6. Talloczy Z,
    7. et al.
    Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther 2018;5:447–62.
    OpenUrl
  15. 15.↵
    1. Pavelka K,
    2. Kivitz A,
    3. Dokoupilova E,
    4. Blanco R,
    5. Maradiaga M,
    6. Tahir H,
    7. et al.
    Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017;19:285.
    OpenUrl
  16. 16.↵
    1. Jahn EM,
    2. Schneider CK
    . How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. N Biotechnol 2009;25:280–6.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Baert F,
    2. Noman M,
    3. Vermeire S,
    4. Van Assche G,
    5. D’ Haens G,
    6. Carbonez A,
    7. et al.
    Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601–8.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Bartelds GM,
    2. Krieckaert CL,
    3. Nurmohamed MT,
    4. van Schouwenburg PA,
    5. Lems WF,
    6. Twisk JW,
    7. et al.
    Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460–8.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Garces S,
    2. Demengeot J,
    3. Benito-Garcia E
    . The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947–55.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Reich K,
    2. Blauvelt A,
    3. Armstrong A,
    4. Langley RG,
    5. Fox T,
    6. Huang J,
    7. et al.
    Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Rheumatol 2017;176:752–8.
    OpenUrl
  21. 21.↵
    1. Klein U,
    2. Liang E,
    3. Vogel B,
    4. Kolbinger F,
    5. Bruin G,
    6. Lloyd P
    . Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients. J Invest Dermatol 2013;133 Suppl 1:S172.
    OpenUrlCrossRef
  22. 22.↵
    1. U.S. Department of Health and Human Services, Food and Drug Administration
    . Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance. [Internet. Accessed September 16, 2019.] Available from: www.regulations.gov/document?D=FDA-2009-D-0539-0002
  23. 23.
    1. European Medicines Agency
    . Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. [Internet. Accessed September 16, 2019.] Available from: www.ema.europa.eu/documents/scientific-guideline/draft-guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-revision-1_en.pdf
  24. 24.
    1. European Medicines Agency
    . Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. [Internet. Accessed September 16, 2019.] Available from: www.ema.europa.eu/documents/scientific-guideline/guideline-immunogenicity-assessment-monoclonal-antibodies-intended-vivo-clinical-use_en.pdf
  25. 25.
    1. Koren E,
    2. Smith HW,
    3. Shores E,
    4. Shankar G,
    5. Finco-Kent D,
    6. Rup B,
    7. et al.
    Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008;333:1–9.
    OpenUrlCrossRefPubMed
  26. 26.
    1. Mire-Sluis AR,
    2. Barrett YC,
    3. Devanarayan V,
    4. Koren E,
    5. Liu H,
    6. Maia M,
    7. et al.
    Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1–16.
    OpenUrlCrossRefPubMed
  27. 27.
    1. Ponce R,
    2. Abad L,
    3. Amaravadi L,
    4. Gelzleichter T,
    5. Gore E,
    6. Green J,
    7. et al.
    Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 2009;54:164–82.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Shankar G,
    2. Devanarayan V,
    3. Amaravadi L,
    4. Barrett YC,
    5. Bowsher R,
    6. Finco-Kent D,
    7. et al.
    Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008;48:1267–81.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Swanson SJ,
    2. Ferbas J,
    3. Mayeux P,
    4. Casadevall N
    . Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004;96:c88–95.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. US Food and Drug Administration
    . Assay development and validation for immunogenicity testing of therapeutic protein products. [Internet. Accessed September 16, 2019.] Available from: www.fda.gov/downloads/drugs/guidances/UCM192750.pdf
  31. 31.↵
    1. Collet-Brose J,
    2. Couble PJ,
    3. Deehan MR,
    4. Nelson RJ,
    5. Ferlin WG,
    6. Lory S
    . Evaluation of multiple immunoassay technology platforms to select the anti-drug antibody assay exhibiting the most appropriate drug and target tolerance. J Immunol Res 2016;2016:5069678.
    OpenUrl
  32. 32.↵
    1. Strand V,
    2. Balsa A,
    3. Al-Saleh J,
    4. Barile-Fabris L,
    5. Horiuchi T,
    6. Takeuchi T,
    7. et al.
    Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs 2017;31:299–316.
    OpenUrl
  33. 33.↵
    1. Snir A,
    2. Kessel A,
    3. Haj T,
    4. Rosner I,
    5. Slobodin G,
    6. Toubi E
    . Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. Clin Exp Rheumatol 2011;29:697–700.
    OpenUrlPubMed
  34. 34.↵
    1. Mihara M,
    2. Ohsugi Y,
    3. Kishimoto T
    . Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. Open Access Rheumatol 2011;3:19–29.
    OpenUrl
  35. 35.↵
    1. Mitsdoerffer M,
    2. Lee Y,
    3. Jäger A,
    4. Kim HJ,
    5. Korn T,
    6. Kolls JK,
    7. et al.
    Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 2010;107:14292–7.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Descotes J
    . Immunotoxicity of monoclonal antibodies. MAbs 2009;1:104–11.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Harding FA,
    2. Stickler MM,
    3. Razo J,
    4. DuBridge RB
    . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010;2:256–65.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Karle A,
    2. Spindeldreher S,
    3. Kolbinger F
    . Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs 2016;8:536–50.
    OpenUrl
  39. 39.↵
    1. Spindeldreher S,
    2. Maillere B,
    3. Correia E,
    4. Tenon M,
    5. Karle A,
    6. Jarvis P,
    7. et al.
    Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol Ther 2018;8:57–68.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Save to my folders

Jump to section

Keywords

SECUKINUMAB
INTERLEUKIN-17A
MONOCLONAL ANTIBODY
IMMUNOGENICITY
PSORIATIC ARTHRITIS
ANKYLOSING SPONDYLITIS

Keywords